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 Nonalcoholic fatty liver disease (NAFLD) is a leading, growing cause of chronic liver 
disease.1 Histologically, NAFLD is a spectrum that ranges from steatosis to steatohepatitis and 
cirrhosis. 2 However, longitudinal cohort studies have consistently shown that fibrosis stage 
alone governs long-term risk for adverse outcomes such as hepatocellular carcinoma and 
decompensated cirrhosis.3, 4  Thus, efficient risk-stratification of patients with NAFLD is key to 
optimize both outcomes and resource utilization.5 Scoring systems such as FIB-4 can define low 
risk cohorts (e.g. FIB-4<1.3) but additional evaluation is needed for patients with intermediate 
and high-risk scores.6  For these patients, vibration-controlled transient elastography (VCTE) is 
powerful, low-cost, point-of-care tool.  
The final frontier of VCTE research is defined by 3 principle questions. First, the 
majority of published experience with VCTE relates to M-probe use, yet 1 in 4 M-probe exams  
fail or are unreliable in NAFLD.7 The ‘XL-probe’ is now widely available but data are limited 
regarding test performance and cutoffs. Second, prospective intention-to-screen data are needed 
to define the optimal testing strategy by body mass index (BMI) in a setting with access to both 
VCTE and magnetic resonance elastography. Third, VCTE yields lower positive predictive 
values (PPV) than negative predictive values (NPV) owing to confounding factors affecting liver 
stiffness including inflammatory activity and hepatosteatosis, albeit controversially, best 
captured by controlled attenuation parameter (CAP).  
 
Karlas et al. performed a patient-level meta-analysis of M-probe VCTE examinations to 
assess the impact of CAP and steatosis in 2,058 patients (18% NAFLD)8. The authors found no 
effect of hepatosteatosis and marginal effects of increasing CAP scores on liver stiffness. Though 
many patients with viral hepatitis were included, the most important data relates to NAFLD 
where cutoffs to achieve 90% sensitivity or specificity for F3-F4 fibrosis were 6.7 kPa or 11.9 
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kPa. Accounting for CAP, the NPV for F3-F4 only rose from 94.3% at CAP 200 dB/m to 95.5% 
at 350 dB/m. CAP adjustment also did not alter the 68% PPV for patients with F3-F4 fibrosis. 
The study limits include the lack of XL-probe data and ALT-based cutoffs for patients with 
NAFLD; conclusions from a cohort (mean BMI 27kg/m2) may not generalize to many clinical 
practices; and true correct-classification rates should derive from intention-to-screen data, 
accounting for screen failures. 
VCTE’s strength is its high NPV for advanced fibrosis. Weaker PPV is its limitation. 
Since PPV is dependent on test-characteristics and the prevalence of advanced fibrosis, efforts to 
improve VCTE’s PPV have two strategic options: adjust for confounders or optimize patient 
selection. Karlas, improving on a prior report from this database by focusing on how results 
impact decision making,9 suggests no benefit for in adjusting VCTE cutoffs using fat-based 
metrics. While a study of ALT-adjusted liver stiffness cutoffs is welcome, to improve VCTE’s 
PPV we have to help the test by selecting higher-risk patients. Building on these data, future 
studies should evaluate cohorts enriched with higher-risk patients (e.g. high FIB-4 scores), using 
XL-probe and intention-to-screen design. 
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